Literature DB >> 20015493

An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction.

Paola Secchiero1, Federica Corallini, Antonio Paolo Beltrami, Claudio Ceconi, Vincenzo Bonasia, Antonio Di Chiara, Roberto Ferrari, Giorgio Zauli.   

Abstract

BACKGROUND: This study was designed to evaluate the biological significance of simultaneous changes in the circulating levels of osteoprotegerin (OPG) and TNF-related apoptosis inducing ligand (TRAIL) in patients with coronary artery disease (CAD), and, in particular, with acute myocardial infarction (AMI).
METHODS: Total levels of OPG and TRAIL were measured by ELISA in patients with AMI (n=113), unstable angina (UA, n=21) and healthy controls (n=120).
RESULTS: Since OPG was elevated during the acute phase (first 12-24-48h) after AMI and in patients with UA with respect to healthy controls, while TRAIL was decreased in acute AMI patients, CAD patients were characterized by an increased OPG/TRAIL ratio. Moreover, the OPG/TRAIL ratio was significantly (p<0.05) higher in the acute AMI patients who developed heart failure (HF) than in those who did not develop HF in the follow-up.
CONCLUSIONS: An impaired OPG/TRAIL ratio after AMI is related to a higher risk of HF. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015493     DOI: 10.1016/j.atherosclerosis.2009.11.005

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  24 in total

1.  TRAIL shows potential cardioprotective activity.

Authors:  Barbara Toffoli; Stella Bernardi; Riccardo Candido; Serena Zacchigna; Bruno Fabris; Paola Secchiero
Journal:  Invest New Drugs       Date:  2011-01-04       Impact factor: 3.850

2.  β-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt.

Authors:  Laurel A Grisanti; Jennifer A Talarico; Rhonda L Carter; Justine E Yu; Ashley A Repas; Scott W Radcliffe; Hoang-Ai Tang; Catherine A Makarewich; Steven R Houser; Douglas G Tilley
Journal:  J Mol Cell Cardiol       Date:  2014-02-22       Impact factor: 5.000

Review 3.  TNF revisited: osteoprotegerin and TNF-related molecules in heart failure.

Authors:  Thor Ueland; Arne Yndestad; Christen P Dahl; Lars Gullestad; Pål Aukrust
Journal:  Curr Heart Fail Rep       Date:  2012-06

4.  Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.

Authors:  Dorette Raaz-Schrauder; Michael G Schrauder; Christian Stumpf; Piotr Lewczuk; Tobias Kilian; Barbara Dietel; Christoph D Garlichs; Christian Schlundt; Stephan Achenbach; Lutz Klinghammer
Journal:  Heart Vessels       Date:  2017-05-31       Impact factor: 2.037

5.  Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype.

Authors:  Veronica Tisato; Giorgio Zauli; Rebecca Voltan; Sergio Gianesini; Maria Grazia di Iasio; Ilaria Volpi; Guido Fiorentini; Paolo Zamboni; Paola Secchiero
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

Review 6.  Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.

Authors:  Fernanda Genre; Raquel López-Mejías; José A Miranda-Filloy; Begoña Ubilla; Beatriz Carnero-López; Ricardo Blanco; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Biomed Res Int       Date:  2014-03-18       Impact factor: 3.411

7.  Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients.

Authors:  Pavel Osmancik; Elena Teringova; Petr Tousek; Petra Paulu; Petr Widimsky
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

8.  Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis.

Authors:  Michael Weichhaus; Prabu Segaran; Ashleigh Renaud; Dirk Geerts; Linda Connelly
Journal:  Cancer Med       Date:  2014-06-28       Impact factor: 4.452

9.  Association of TRAIL and Its Receptors with Large-Artery Atherosclerotic Stroke.

Authors:  Xudong Pan; Meng Pang; Aijun Ma; Kun Wang; Zhang Zhang; Qianwei Zhong; Shuna Yang
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

10.  Osteoprotegerin and TRAIL in Acute Onset of Atrial Fibrillation.

Authors:  Krzysztof Rewiuk; Tomasz Grodzicki
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.